EE200100167A - 4-amino-asendatud 2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid - Google Patents

4-amino-asendatud 2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid

Info

Publication number
EE200100167A
EE200100167A EEP200100167A EEP200100167A EE200100167A EE 200100167 A EE200100167 A EE 200100167A EE P200100167 A EEP200100167 A EE P200100167A EE P200100167 A EEP200100167 A EE P200100167A EE 200100167 A EE200100167 A EE 200100167A
Authority
EE
Estonia
Prior art keywords
substituted
tetrahydroquinolines
amino
cetp inhibitors
cetp
Prior art date
Application number
EEP200100167A
Other languages
English (en)
Estonian (et)
Inventor
Paul Deninno Michael
Tetteh Magnus-Aryitey George
Benjamin Ruggeri Roger
Thure Wester Ronald
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200100167A publication Critical patent/EE200100167A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
EEP200100167A 1998-09-17 1999-09-10 4-amino-asendatud 2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid EE200100167A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10092798P 1998-09-17 1998-09-17
PCT/IB1999/001534 WO2000017165A1 (fr) 1998-09-17 1999-09-10 4-amino substitue-2-substitue-1,2,3,4-tetrahydroquinolines utilisees comme inhibiteurs de cetp

Publications (1)

Publication Number Publication Date
EE200100167A true EE200100167A (et) 2002-06-17

Family

ID=22282246

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100167A EE200100167A (et) 1998-09-17 1999-09-10 4-amino-asendatud 2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid

Country Status (50)

Country Link
US (2) US6140343A (fr)
EP (1) EP1114032B1 (fr)
JP (1) JP3561474B2 (fr)
KR (1) KR100422286B1 (fr)
CN (2) CN1515259A (fr)
AP (1) AP1345A (fr)
AR (1) AR030523A1 (fr)
AT (1) ATE268324T1 (fr)
AU (1) AU747715B2 (fr)
BG (1) BG65101B1 (fr)
BR (1) BR9913855A (fr)
CA (1) CA2344248C (fr)
CO (1) CO5290250A1 (fr)
CR (1) CR6306A (fr)
CU (1) CU23053A3 (fr)
CZ (1) CZ2001954A3 (fr)
DE (1) DE69917790T2 (fr)
DK (1) DK1114032T3 (fr)
DZ (1) DZ2891A1 (fr)
EA (1) EA005761B1 (fr)
EE (1) EE200100167A (fr)
ES (1) ES2221420T3 (fr)
GC (1) GC0000108A (fr)
GE (1) GEP20032973B (fr)
GT (1) GT199900147A (fr)
HK (1) HK1039938A1 (fr)
HR (1) HRP20010200B1 (fr)
HU (1) HUP0103512A3 (fr)
ID (1) ID27838A (fr)
IL (1) IL141388A0 (fr)
IS (1) IS2278B (fr)
MA (1) MA26689A1 (fr)
MY (1) MY121405A (fr)
NO (1) NO319781B1 (fr)
NZ (1) NZ509837A (fr)
OA (1) OA11651A (fr)
PA (1) PA8481201A1 (fr)
PE (1) PE20001054A1 (fr)
PL (1) PL198124B1 (fr)
PT (1) PT1114032E (fr)
SI (1) SI1114032T1 (fr)
SK (1) SK3532001A3 (fr)
SV (1) SV1999000150A (fr)
TN (1) TNSN99170A1 (fr)
TR (1) TR200100780T2 (fr)
TW (1) TW502022B (fr)
UA (1) UA70960C2 (fr)
WO (1) WO2000017165A1 (fr)
YU (1) YU18101A (fr)
ZA (1) ZA200101745B (fr)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US7115279B2 (en) 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
SE0101161D0 (sv) * 2001-03-30 2001-03-30 Astrazeneca Ab New compounds
JP4334233B2 (ja) * 2001-04-11 2009-09-30 アセロジエニクス・インコーポレイテツド プロブコールモノエステルによって血漿ｈｄｌコレステロールレベルを上昇させ、ｈｄｌの機能性を改善するための方法
AU2002253448B2 (en) 2001-04-30 2007-07-05 Pfizer Products Inc. Compounds useful as intermediates for 4-aminoquinoline derivatives
BR0210505A (pt) * 2001-06-21 2004-05-18 Pfizer Prod Inc Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo
DE60233874D1 (de) * 2001-06-22 2009-11-12 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
BR0210519A (pt) 2001-06-22 2004-06-22 Pfizer Prod Inc Composições farmacêuticas de adsorvatos de fármaco amorfo
EP1269994A3 (fr) 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
HUP0500165A2 (en) * 2001-12-19 2006-09-28 Atherogenics Inc Chalcone derivatives and their use to treat diseases
WO2003053359A2 (fr) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(phenyl-substitue)-2-propyne-1-ones et leur utilisation pour le traitement d'affections
WO2003055482A1 (fr) * 2001-12-21 2003-07-10 Novo Nordisk A/S Derives amide utiles en tant qu'activateurs de la glucokinase
BR0307344A (pt) * 2002-02-01 2004-12-14 Pfizer Prod Inc Composições farmacêuticas de dispersões amorfas de fármacos e materiais formadores de microfase lipofìlica
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
PT1469833T (pt) * 2002-02-01 2021-07-13 Bend Res Inc Método para produzir dispersões de fármaco amorfo sólido seco por pulverização homogéneas utilizando aparelho de secagem por pulverização modificado
ES2309294T3 (es) * 2002-02-01 2008-12-16 Pfizer Products Inc. Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferecncia de ester de colesterilo.
CA2744893A1 (fr) * 2002-06-27 2004-01-08 Novo Nordisk A/S Derives d'arylcarbonyle servant d'activateurs de glucokinase
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
BR0315041A (pt) 2002-10-04 2005-08-16 Millennium Pharm Inc Métodos para inibir crth2 em um indivìduo que necessita inibição de crth2; composto; e composição farmacêutica
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
ATE327977T1 (de) * 2002-10-21 2006-06-15 Warner Lambert Co Tetrahydrochinolin-derivate als crth2 antagonisten
AU2003289207A1 (en) * 2002-12-06 2004-06-30 Kyowa Hakko Kogyo Co., Ltd. Anti-inflammatory agent
AU2003303239A1 (en) * 2002-12-19 2004-07-14 Atherogenics, Inc. Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
AU2003283769A1 (en) 2002-12-20 2004-07-14 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
EP1435356A1 (fr) * 2003-01-06 2004-07-07 Warner-Lambert Company LLC Dérivés de la quinoléine en tant qu'antagonistes de CRTH2
WO2004072042A2 (fr) * 2003-02-12 2004-08-26 Carex S.A. Modulation de l'activite de recepteurs nucleaires
MXPA05009848A (es) 2003-03-17 2005-12-06 Japan Tobacco Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia del ester de colesterilo.
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
WO2004085401A1 (fr) * 2003-03-28 2004-10-07 Pfizer Products Inc. Derives de 1,2,3,4-tetrahydro- et 1,2 dihydro-quinoleine et 1,2,3,4-tetrahydro-quinoxaline 1,2,4-substitues, utiles comme inhibiteurs de cetp pour le traitement de l'atherosclerose et de l'obesite
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
WO2004106299A2 (fr) 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Derives pyrroliques substitues
WO2005011635A2 (fr) 2003-08-04 2005-02-10 Pfizer Products Inc. Compositions pharmaceutiques a base d'adsorbats de medicaments amorphes et de produits aptes a former des microphases lipophiles
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
WO2005030185A2 (fr) 2003-09-26 2005-04-07 Japan Tobacco Inc. Procede pour inhiber la production de lipoproteines restantes
EP1670765A2 (fr) * 2003-09-30 2006-06-21 Pfizer Products Inc. Inhibiteurs de la proteine de transfert d'ester de cholesteryle (cetp) et leurs metabolites
KR20060085675A (ko) * 2003-10-08 2006-07-27 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
WO2005046662A2 (fr) * 2003-11-07 2005-05-26 Jj Pharma, Inc. Complexes pour une therapie combinatoire stimulant les hdl
MXPA06007667A (es) * 2004-01-06 2006-09-01 Novo Nordisk As Heteroaril-ureas y su uso como activadores de glucocinasa.
AU2005221656B2 (en) 2004-03-05 2011-06-23 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
PT1732933E (pt) 2004-03-26 2008-10-20 Lilly Co Eli Compostos para o tratamento da dislipidémia
TWI345568B (en) 2004-04-02 2011-07-21 Mitsubishi Tanabe Pharma Corp Tetrahydronaphthyridine derivatives and a process for preparing the same
UA90269C2 (ru) 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
US20050282812A1 (en) * 2004-06-18 2005-12-22 JONES Zachary Inhibitors of cholesteryl ester transfer protein
KR100859223B1 (ko) * 2004-06-24 2008-09-18 일라이 릴리 앤드 캄파니 이상지혈증 치료를 위한 화합물 및 방법
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
US20060063828A1 (en) * 2004-06-28 2006-03-23 Weingarten M D 1,2-Bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
DOP2005000123A (es) 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
JP2008510835A (ja) * 2004-08-25 2008-04-10 エッセンシャリス，インク． カリウムａｔｐチャンネル開放因子の製剤処方、及びその使用
US20070149567A1 (en) * 2004-09-23 2007-06-28 Pfizer Inc Quinoline compounds
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
ATE439347T1 (de) * 2004-11-23 2009-08-15 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihydroxy-heptansäure- derivate als hmg-co-a-reductase-inhibitoren zur behandlung von lipidemia
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
KR101238525B1 (ko) 2004-12-31 2013-02-28 레디 유에스 테라퓨틱스 인코포레이티드 Ｃｅｔｐ 저해제로서의 신규 벤질아민 유도체
EP2548894A1 (fr) 2005-02-03 2013-01-23 Bend Research, Inc. Compositions pharmaceutiques à éfficacité améliorée
ZA200707498B (en) 2005-02-24 2008-11-26 Millennium Pharm Inc PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2006098394A1 (fr) * 2005-03-14 2006-09-21 Japan Tobacco Inc. Méthode pour inhiber l’absorption de lipides et l’inhibiteur de l'absorption de lipides
WO2007005572A1 (fr) * 2005-07-01 2007-01-11 Merck & Co., Inc. Procede permettant d'effectuer la synthese d'un inhibiteur de cetp
ATE547396T1 (de) * 2005-07-08 2012-03-15 Novo Nordisk As Dicycloalkylcarbamoyl-harnstoffe als glucokinase- aktivatoren
WO2007006760A1 (fr) * 2005-07-08 2007-01-18 Novo Nordisk A/S Activateurs de dicycloalkylurée glucokinase
EP1904467B1 (fr) 2005-07-14 2013-05-01 Novo Nordisk A/S Activateurs de l'urée glucokinase
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
JP4531027B2 (ja) * 2005-09-29 2010-08-25 田辺三菱製薬株式会社 医薬組成物
JP4681526B2 (ja) * 2005-09-29 2011-05-11 田辺三菱製薬株式会社 医薬組成物
WO2007048027A2 (fr) 2005-10-21 2007-04-26 Novartis Ag Combinaison de composes organiques
KR101329112B1 (ko) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
PL1968601T3 (pl) 2006-01-05 2012-03-30 Essentialis Inc Sole związków otwierających kanały potasowe ATP i ich zastosowanie
UY30118A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
UY30117A1 (es) 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compuesto amina trisustituido
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
GB0615670D0 (en) * 2006-08-07 2006-09-13 Syngenta Participations Ag Chemical compounds
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
WO2008045564A2 (fr) * 2006-10-12 2008-04-17 Epix Delaware, Inc. Composés de carboxamide et leur utilisation
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
US8138185B2 (en) * 2007-01-09 2012-03-20 Novo Nordisk A/S Urea glucokinase activators
US8318778B2 (en) * 2007-01-11 2012-11-27 Novo Nordisk A/S Urea glucokinase activators
CN101220021B (zh) * 2007-01-12 2010-12-08 上海医药工业研究院 4-取代苯氧基喹啉类化合物及其中间体、制备方法和应用
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
JP5244095B2 (ja) 2007-04-13 2013-07-24 興和株式会社 新規なジベンジルアミン構造を有するピリミジン化合物及びこれを含有する医薬
AU2008272923A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
EP2207775B1 (fr) 2007-11-05 2012-03-21 Novartis AG Dérivés de 4-benzylamino-1-carboxyacyl-pipéridine en tant qu'inhibiteurs de cetp utiles pour le traitement de maladies telles que l'hyperlipidémie ou l'artériosclérose
EP2229356B1 (fr) 2007-12-03 2011-10-12 Novartis AG Dérivés de 4-benzylaminopyrrolidine 1,2-disubstituée comme inhibiteurs de cetp utiles pour le traitement de maladies telles que l'hyperlipidémie ou l'artériosclérose
RU2010128543A (ru) 2007-12-11 2012-01-20 Сайтопатфайндер, Инк. (Jp) Карбоксамидные соединения и их применение в качестве агонистов хемокиновых рецепторов
CN102459247B (zh) 2009-05-15 2014-09-17 诺华股份有限公司 作为醛固酮合酶抑制剂的苯并噁唑酮衍生物
JP5659224B2 (ja) 2009-05-15 2015-01-28 ノバルティス アーゲー アルドステロンシンターゼ阻害剤としてのアリールピリジン
SG176010A1 (en) 2009-05-28 2011-12-29 Novartis Ag Substituted aminobutyric derivatives as neprilysin inhibitors
AU2010251967B9 (en) 2009-05-28 2014-04-03 Novartis Ag Substituted aminopropionic derivatives as neprilysin inhibitors
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
ES2663351T3 (es) 2009-11-17 2018-04-12 Novartis Ag Derivados de aril-piridina como inhibidores de la aldosterona sintasa
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja) 2009-11-30 2014-08-20 ノバルティス アーゲー アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
WO2011145022A1 (fr) 2010-05-21 2011-11-24 Pfizer Inc. 2-phénylbenzoylamides
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
US8877815B2 (en) 2010-11-16 2014-11-04 Novartis Ag Substituted carbamoylcycloalkyl acetic acid derivatives as NEP
ES2648788T3 (es) 2011-01-26 2018-01-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Método para evaluar el riesgo de un sujeto de tener una enfermedad cardiovascular
EP2680874A2 (fr) 2011-03-04 2014-01-08 Pfizer Inc Peptides de type edn3 et utilisations associées
MX2013014900A (es) 2011-06-17 2014-02-17 Merck Sharp & Dohme Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de la molecula receptora homologa quimioatrayente expresada en celulas t auxiliares de tipo 2.
AR087451A1 (es) * 2011-08-17 2014-03-26 Lilly Co Eli Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
CA2845284C (fr) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Composes amines heterocycliques substitues comme inhibiteurs de la proteine de transfert d'ester cholesterylique (cetp)
KR101803866B1 (ko) 2011-09-27 2017-12-04 닥터 레디스 레보러터리즈 리미티드 동맥경화증 치료에 유용한 콜레스테릴 에스테르-전달 단백질(cetp) 억제제로서 5-벤질아미노메틸-6-아미노피라졸로[3,4-b]피리딘 유도체
MX347400B (es) 2012-06-29 2017-04-18 Univ Nac Autónoma De México Vacuna de aplicacion nasal contra el desarrollo de la enfermedad aterosclerotica y el higado graso.
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
JP6295277B2 (ja) 2013-02-14 2018-03-14 ノバルティス アーゲー Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体
WO2014170786A1 (fr) 2013-04-17 2014-10-23 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
AU2014293387B2 (en) 2013-07-25 2017-04-20 Novartis Ag Bioconjugates of synthetic apelin polypeptides
KR20160031551A (ko) 2013-07-25 2016-03-22 노파르티스 아게 심부전의 치료를 위한 시클릭 폴리펩티드
AU2015307306B2 (en) * 2014-08-28 2021-01-21 Newamsterdam Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and HMG CoA reductase inhibitors
MX2017002610A (es) 2014-08-29 2017-10-11 Tes Pharma S R L INHIBIDORES DE ACIDO A-AMINO-ß-CARBOXIMUCONICO SEMIALDEHIDO DESCARBOXILASA.
WO2016055901A1 (fr) 2014-10-08 2016-04-14 Pfizer Inc. Composés d'amide substitué
EA201791668A1 (ru) 2015-01-23 2017-11-30 Новартис Аг Синтетические конъюгаты апелина с жирной кислотой с улучшенным периодом полураспада
JOP20190086A1 (ar) 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN112040945A (zh) 2018-06-12 2020-12-04 Vtv治疗有限责任公司 葡萄糖激酶激活剂与胰岛素或胰岛素类似物组合的治疗用途
CN113574055A (zh) 2019-01-18 2021-10-29 阿斯利康(瑞典)有限公司 Pcsk9抑制剂及其使用方法
AR127698A1 (es) 2021-11-23 2024-02-21 Novartis Ag Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
US5276168A (en) * 1990-06-18 1994-01-04 E. R. Squibb & Sons, Inc. Benzopyran derivatives and heterocyclic analogs thereof as antiischemic agents
US5401848A (en) 1990-11-26 1995-03-28 E. R. Squibb & Sons, Inc. Indane and quinoline derivatives
JPH0676403B2 (ja) * 1991-01-18 1994-09-28 エスエス製薬株式会社 新規なベンゾ［５，６ シクロヘプタ［１，２−ｂ ピリジン誘導体及びこれを含有する抗アレルギー剤
US5288725A (en) * 1992-10-15 1994-02-22 Merck & Co., Inc. Pyrroloquinoline Bradykinin antagonist
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6462091B1 (en) 1998-12-23 2002-10-08 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and HMG coA reductase inhibitors for cardiovascular indications

Also Published As

Publication number Publication date
AU5440399A (en) 2000-04-10
IS2278B (is) 2007-09-15
TR200100780T2 (tr) 2001-07-23
JP3561474B2 (ja) 2004-09-02
HK1039938A1 (zh) 2002-05-17
DZ2891A1 (fr) 2003-12-15
AR030523A1 (es) 2003-08-27
JP2002526476A (ja) 2002-08-20
CN1515259A (zh) 2004-07-28
UA70960C2 (uk) 2004-11-15
PA8481201A1 (es) 2000-09-29
GT199900147A (es) 1999-09-06
CA2344248C (fr) 2007-01-09
CZ2001954A3 (cs) 2001-12-12
ATE268324T1 (de) 2004-06-15
KR20010085814A (ko) 2001-09-07
NO20011349D0 (no) 2001-03-16
KR100422286B1 (ko) 2004-03-11
EP1114032A1 (fr) 2001-07-11
EP1114032B1 (fr) 2004-06-02
HUP0103512A2 (hu) 2002-02-28
DE69917790D1 (de) 2004-07-08
SK3532001A3 (en) 2001-12-03
TNSN99170A1 (fr) 2005-11-10
HRP20010200A2 (en) 2002-04-30
PL346830A1 (en) 2002-02-25
NO20011349L (no) 2001-05-14
SV1999000150A (es) 2000-06-06
PL198124B1 (pl) 2008-05-30
HUP0103512A3 (en) 2002-03-28
CA2344248A1 (fr) 2000-03-30
BG105429A (en) 2001-12-29
MA26689A1 (fr) 2004-12-20
CU23053A3 (es) 2005-06-24
YU18101A (sh) 2004-05-12
SI1114032T1 (fr) 2004-12-31
TW502022B (en) 2002-09-11
CN1318057A (zh) 2001-10-17
AU747715B2 (en) 2002-05-23
NO319781B1 (no) 2005-09-12
EA005761B1 (ru) 2005-06-30
DK1114032T3 (da) 2004-08-16
PE20001054A1 (es) 2000-10-14
AP1345A (en) 2004-12-15
ID27838A (id) 2001-04-26
EA200100249A1 (ru) 2001-08-27
BR9913855A (pt) 2001-07-24
US6489478B1 (en) 2002-12-03
ZA200101745B (en) 2002-05-02
WO2000017165A1 (fr) 2000-03-30
DE69917790T2 (de) 2005-06-09
ES2221420T3 (es) 2004-12-16
CO5290250A1 (es) 2003-06-27
NZ509837A (en) 2002-11-26
US6140343A (en) 2000-10-31
GEP20032973B (en) 2003-05-27
HRP20010200B1 (en) 2006-10-31
IL141388A0 (en) 2002-03-10
CR6306A (es) 2003-08-28
GC0000108A (en) 2005-06-29
IS5858A (is) 2001-02-23
MY121405A (en) 2006-01-28
OA11651A (en) 2004-12-07
PT1114032E (pt) 2004-09-30
BG65101B1 (bg) 2007-02-28
AP2001002100A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
EE200100167A (et) 4-amino-asendatud 2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid
EE200100166A (et) 4-karboksüamino-2-asendatud 1, 2, 3, 4-tetrahüdrokinoliinid kui CETP inhibiitorid
DK1114033T3 (da) 4-Carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoliner som CETP-inhibitorer
ATE240327T1 (de) 1,2-annelierte chinolinderivate
NO20013003D0 (no) Kinolin-derivater
DK1073639T3 (da) Chinolinderivater
ATE250036T1 (de) Chinolinderivate
DK1104420T3 (da) Substituerede 1,8-naphthyridin-4(1H)-oner som phosphodiesterase-4-inhibitorer
ATE229005T1 (de) Chinolinderivate
EE200100039A (et) Ftalasiinderivaadid kui fosfodiesteraas-4 inhibiitorid
SI1114031T1 (en) 4-carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines as cetp inhibitors

Legal Events

Date Code Title Description
HK1A Erratum in gazette